London, United Kingdom

Ivan Nemazanyy

USPTO Granted Patents = 1 


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ivan Nemazanyy: Innovator in mTOR Research

Introduction

Ivan Nemazanyy is a notable inventor based in London, GB. He has made significant contributions to the field of molecular biology, particularly in the study of the mammalian target of rapamycin (mTOR) protein. His innovative work has implications for understanding and treating various diseases.

Latest Patents

Ivan Nemazanyy holds a patent for a truncated variant of the mammalian target for rapamycin (mTOR) protein. This invention relates to mTORbeta, a splice form of mTOR, along with nucleic acids encoding mTOR beta and antibodies against mTOR beta. The patent also covers methods for producing mTOR beta and screening for agents that modulate mTOR beta expression and/or activity. Furthermore, it includes a method for treating diseases associated with aberrant expression of mTOR beta through the administration of agents that alter mTOR activity and/or expression. He has 1 patent to his name.

Career Highlights

Throughout his career, Ivan has worked with prominent organizations such as UCL Business Plc and the Ludwig Institute for Cancer Research Limited. His experience in these institutions has allowed him to advance his research and contribute to significant scientific discoveries.

Collaborations

Ivan has collaborated with notable colleagues, including Ganna Panasyuk and Alexander Zhyvoloup. These partnerships have enriched his research endeavors and fostered innovation in the field.

Conclusion

Ivan Nemazanyy is a distinguished inventor whose work on mTORbeta has the potential to impact medical science significantly. His contributions to the understanding of mTOR protein and its implications for disease treatment highlight the importance of innovation in research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…